Fusion Antibodies (LON:FAB) Shares Up 9.2% – What’s Next?

Fusion Antibodies plc (LON:FAB)’s stock price traded up 9.2% on Tuesday . The stock traded as high as GBX 17.29 and last traded at GBX 16.66. 1,439,924 shares traded hands during trading, an increase of 25% from the average session volume of 1,150,315 shares. The stock had previously closed at GBX 15.25.

Fusion Antibodies Stock Up 9.2%

The stock has a market capitalization of £18.94 million, a PE ratio of -11.11 and a beta of 0.49. The stock’s fifty day simple moving average is GBX 13.87 and its 200-day simple moving average is GBX 11.99. The company has a current ratio of 3.87, a quick ratio of 2.36 and a debt-to-equity ratio of 2.40.

Fusion Antibodies (LON:FAB) last posted its quarterly earnings data on Monday, November 24th. The company reported GBX (0.50) EPS for the quarter. Fusion Antibodies had a negative net margin of 195.95% and a negative return on equity of 137.11%. As a group, sell-side analysts forecast that Fusion Antibodies plc will post -129.9999875 EPS for the current fiscal year.

Fusion Antibodies Company Profile

Fusion is a Belfast based contract research organisation (“CRO”) providing a range of antibody engineering services for the development of antibodies for both therapeutic drug and diagnostic applications.

The Company’s ordinary shares were admitted to trading on AIM on 18 December 2017. Fusion provides a broad range of services in antibody generation, development, production, characterisation and optimisation.